BioNTech: 1st Patient Dosed in Phase 2 Trial of mRNA Colorectal Cancer Immunotherapy

 Second Phase 2 trial initiated from BioNTech's proprietary individualized

      mRNA-based cancer vaccine platform iNeST 
 
   -- Randomized Phase 2 trial will enroll approximately 200 patients with 
      high-risk colorectal cancer that are circulating tumor DNA positive after 
      adjuvant treatment 
 
   -- BioNTech-sponsored trial is initiated in the United States, Germany, 
      Spain and Belgium and is enrolling patients immediately 
 
   -- BioNTech will continue joint development of BNT122 (autogene cevumeran, 
      RO7198457) with Genentech, a member of the Roche Group, in other trials 

BioNTech SE (NASDAQ: BNTX, "BioNTech" or "the Company"), announced today that the first colorectal cancer patient has been treated with its individualized mRNA cancer vaccine BNT122 (autogene cevumeran, RO7198457) in a Phase 2 clinical trial. The trial has been initiated in the United States, Germany, Spain and Belgium. It is planned to enroll about 200 patients to evaluate the efficacy of RO7198457 (BNT122) compared to watchful waiting after surgery and chemotherapy, the current standard of care for these high-risk patients. As the second deadliest cancer worldwide, the medical need for novel therapies to treat colorectal cancer remains high.

https://www.marketscreener.com/quote/stock/BIONTECH-SE-66771992/news/Press-Release-BioNTech-Expands-Clinical-Oncology-Portfolio-with-First-Patient-Dosed-in-Phase-2-Tri-36566210/